Skip to main content

Advertisement

SpringerLink
Log in

Light-activated genetic therapy to treat blindness enters clinic

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A Publisher Correction to this article was published on 01 March 2021

This article has been updated

Novartis is betting that optogenetics, a technology used by researchers to control cell signaling, is ready for the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

Author information

Authors and Affiliations

  1. Tequesta, FL, USA

    Mark Ratner

Authors
  1. Mark Ratner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ratner, M. Light-activated genetic therapy to treat blindness enters clinic. Nat Biotechnol 39, 126–127 (2021). https://doi.org/10.1038/s41587-021-00823-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-00823-9

  • Springer Nature America, Inc.

Search

Navigation